Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IL-2 fusion protein produces remission in late-stage refractory CTCL

June 23, 1998

Novopharm Biotech's NOVOMAb-G2 IgM completes phase I

June 23, 1998

Russian scientists evaluate the antitumor activity of betaleukin

June 22, 1998

CBER requests additional information for Ontak BLA

June 19, 1998

ICO25 MAb suppresses tumor growth and prolongs survival in preclinical model of colon cancer

June 19, 1998

New dosing regimen of Avax melanoma vaccine results in improved outcome

June 17, 1998

Biomira and Chiron expand Theratope cancer vaccine agreement

June 17, 1998

Combination immunotherapy of renal cell carcinoma: efficacy established in phase II trial

June 11, 1998

Excellent phase III results reported for bropirimine in CIS

June 11, 1998

Encouraging results reported for Cel-Sci's Multikine

June 11, 1998

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....